Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
5-day change
1st Jan Change
1.25
USD
-2.34%
-5.30%
-50.00%
Presentation Operator MessageOperator (Operator)Greetings, and welcome to Ekso Bionics Third Q...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Certain Warrants of Ekso Bionics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2024.
Mar. 16
CI
Certain Common Stock of Ekso Bionics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2024.
Mar. 16
CI
HC Wainwright Trims Price Target on Ekso Bionics to $9.25 From $10, Keeps Buy Rating
Mar. 05
MT
Transcript : Ekso Bionics Holdings, Inc., Q4 2023 Earnings Call, Mar 04, 2024
Mar. 04
Ekso Bionics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 04
CI
Ekso Bionics Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 04
CI
HC Wainwright Adjusts Ekso Bionics Holdings' Price Target to $10 From $9, Keeps Buy Rating
Jan. 22
MT
Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR
Jan. 08
CI
Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023
Jan. 04
CI
Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal
Dec. 12
CI
Transcript : Ekso Bionics Holdings, Inc., Q3 2023 Earnings Call, Oct 26, 2023
23-10-26
Earnings Flash (EKSO) EKSO BIONICS HOLDINGS Posts Q3 Revenue $4.6M, vs. Street Est of $4.53M
23-10-26
MT
Ekso Bionics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-26
CI
Transcript : Ekso Bionics Holdings, Inc., Q2 2023 Earnings Call, Jul 27, 2023
23-07-27
Earnings Flash (EKSO) EKSO BIONICS HOLDINGS Reports Q2 Revenue $4.7M, vs. Street Est of $4.35M
23-07-27
MT
Ekso Bionics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-07-27
CI
Transcript : Ekso Bionics Holdings, Inc., Q1 2023 Earnings Call, Apr 27, 2023
23-04-27
Ekso Bionics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-27
CI
Earnings Flash (EKSO) EKSO BIONICS HOLDINGS Posts Q1 Revenue $4.1M, vs. Street Est of $2.8M
23-04-27
MT
Ekso Bionics Holdings, Inc. Announces Resignation of Stanley Stern from the Board, Effective on April 26, 2023
23-04-26
CI
Transcript : Ekso Bionics Holdings, Inc., Q4 2022 Earnings Call, Mar 28, 2023
23-03-28
Ekso Bionics Holdings, Inc Announces Director Changes
22-12-09
CI
Ekso Bionics Buys Parker Hannifin's Human Motion, Control Business for $10 Million; Names Davis CEO
22-12-05
MT
Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.
22-12-04
CI
Transcript : Ekso Bionics Holdings, Inc., Q3 2022 Earnings Call, Nov 03, 2022
22-11-03
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.
More about the company
Last Close Price
1.25
USD
Average target price
9.25
USD
Spread / Average Target
+640.00%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1